303.4 ๐Ÿ“‹ ็ซ ๆœซ้€Ÿ่จ˜ Summary

303.4.1 ๐Ÿ”‘ ไธ€ๅฅ่ฉฑ็ธฝ็ต

ๅ‘ผๅธ็ณป็ตฑ่จบๆ–ทๅทฅๅ…ท๏ผšimaging๏ผˆCXR first-lineใ€HRCT for ILDใ€CTPA for PEใ€V/Q for pregnancy/CKDใ€PET-CT for cancerใ€lung ultrasound bedside game-changer๏ผ‰๏ผ›PFT๏ผˆspirometry obstructive vs restrictiveใ€lung volumesใ€DLCOใ€methacholine challenge for asthmaใ€6MWTใ€CPET๏ผ‰๏ผ›bronchoscopy๏ผˆflexibleใ€rigidใ€EBUS for mediastinal LNใ€cryobiopsy for ILDใ€navigational/robotic for peripheral๏ผ‰๏ผ›pleural fluid๏ผˆLightโ€™s criteria exudate๏ผ‰๏ผ›molecular๏ผˆNSCLC EGFR/ALK/ROS1/KRAS G12C/MET/BRAF/NTRK/PD-L1๏ผ‰๏ผ›sleep๏ผˆPSG gold standardใ€HSAT for uncomplicated๏ผ‰๏ผ›2024-2026 ่ถจๅ‹ข๏ผšrobotic bronchoscopy (Monarch/Ion) + AI image analysis + organoid cultureใ€‚

303.4.2 ๐Ÿ’Š ๆฒป็™‚็ฒพ่ฆ

  • diagnostic workflow๏ผš็—‡็‹€ โ†’ CXR โ†’ HRCT / CTPA / PFT / bronchoscopy ไพ้œ€่ฆ
  • ILD๏ผšHRCT ๅ…ˆ๏ผˆUIP pattern = IPF๏ผ‰๏ผŒcryobiopsy ๆˆ– surgical ไธ็ขบๅฎšๆ™‚
  • PE๏ผšCTPA gold standard๏ผ›pregnancy / CKD ็”จ V/Q scan
  • NSCLC๏ผštissue biopsy + molecular profiling๏ผˆliquid biopsy ๅฏ่ฃœๅผท๏ผ‰
  • pleural fluid๏ผšthoracentesis + Lightโ€™s criteria + cell count + chemistry + culture + cytology + ADA
  • sleep apnea๏ผšPSG > HSAT๏ผ›CPAP for OSA

303.4.3 ๐ŸŽฏ ็›ง้†ซๅธซ็š„่€ƒๅ‰ๆ้†’

  1. PFT ไธ‰ๅคง pattern๏ผšobstructive (FEV1/FVC < 0.7)ใ€restrictive (TLC < 80%)ใ€mixed๏ผ›bronchodilator reversibility > 12% AND > 200 mL FEV1 = asthma
  2. methacholine challenge ็”จๆ–ผ spirometry ๆญฃๅธธไฝ†ๆ‡ท็–‘ asthma๏ผ›PC20 โ‰ค 8 mg/mL = positive
  3. Lightโ€™s criteria for exudate๏ผšpleural/serum protein > 0.5 OR pleural/serum LDH > 0.6 OR pleural LDH > 2/3 upper limit serum๏ผ›ADA > 40 = TB pleurisy
  4. BAL ็ดฐ่ƒžๅญธ patterns๏ผšsarcoid๏ผˆlymphocytic CD4/CD8 > 4๏ผ‰ใ€HP๏ผˆlymphocytic CD4/CD8 < 1๏ผ‰ใ€eosinophilic pneumonia๏ผˆ> 25%๏ผ‰ใ€bacterial๏ผˆneutrophilic๏ผ‰ใ€alveolar hemorrhage๏ผˆhemosiderin macrophages๏ผ‰ใ€PAP๏ผˆmilky + PAS+๏ผ‰
  5. NSCLC ๅˆ†ๅญๆชขๆธฌๅฟ…ๅš๏ผšEGFR (osimertinib)ใ€ALK (alectinib)ใ€ROS1 (crizotinib)ใ€KRAS G12C (sotorasib, adagrasib)ใ€MET exon 14 (capmatinib)ใ€BRAF V600E (dabrafenib + trametinib)ใ€NTRK (larotrectinib)ใ€HER2 (trastuzumab deruxtecan)ใ€PD-L1
  6. HRCT ๆ˜ฏ ILD diagnosis gold standard๏ผšUIP pattern (honeycomb + reticular + sub-pleural basal predominance) โ†’ ไธๅฟ… biopsy ๅณๅฏ่จบๆ–ท IPF
  7. robotic bronchoscopy (Monarch, Ion) 2024-2026 ๆ”นๅฏซ peripheral pulmonary nodule diagnosis โ€” ๆฏ” CT-guided ๅฎ‰ๅ…จ
  8. lung ultrasound ๅบŠ้‚Š BLUE protocol๏ผšA-lines (normal)ใ€B-lines (interstitial fluid/edema)ใ€consolidationใ€no pleural sliding (pneumothorax)
  9. DLCO ่งฃ่ฎ€๏ผšobstruction + โ†“ DLCO = emphysema๏ผ›restriction + โ†“ DLCO = ILD๏ผ›isolated โ†“ DLCO = pulmonary HTN ๆˆ– anemia๏ผ›โ†‘ DLCO = alveolar hemorrhageใ€polycythemiaใ€asthma
  10. lung cancer screening USPSTF 2021๏ผš50-80 yo + โ‰ฅ 20 pack-year + current smoker ๆˆ– quit < 15 yr โ†’ annual LDCT